Search Results - "Kalathoor, Sujay"

Mild Innate Immune Activation Overrides Efficient Nanoparticle‐Mediated RNA Delivery by Lokugamage, Melissa P., Gan, Zubao, Zurla, Chiara, Levin, Joel, Islam, Fatima Z., Kalathoor, Sujay, Sato, Manaka, Sago, Cory D., Santangelo, Philip J., Dahlman, James E.

“…Clinical mRNA delivery remains challenging, in large part because how physiology alters delivery in vivo remains underexplored. For example, mRNA delivered by…”
Get full text

Nanoparticles Containing Oxidized Cholesterol Deliver mRNA to the Liver Microenvironment at Clinically Relevant Doses by Paunovska, Kalina, Da Silva Sanchez, Alejandro J., Sago, Cory D., Gan, Zubao, Lokugamage, Melissa P., Islam, Fatima Z., Kalathoor, Sujay, Krupczak, Brandon R., Dahlman, James E.

“…Using mRNA to produce therapeutic proteins is a promising approach to treat genetic diseases. However, systemically delivering mRNA to cell types besides…”
Get full text

A Direct Comparison of in Vitro and in Vivo Nucleic Acid Delivery Mediated by Hundreds of Nanoparticles Reveals a Weak Correlation by Paunovska, Kalina, Sago, Cory D, Monaco, Christopher M, Hudson, William H, Castro, Marielena Gamboa, Rudoltz, Tobi G, Kalathoor, Sujay, Vanover, Daryll A, Santangelo, Philip J, Ahmed, Rafi, Bryksin, Anton V, Dahlman, James E

“…Endothelial cells and macrophages play active roles in disease and as a result are important targets for nucleic acid therapies. While thousands of chemically…”
Get full text

Augmented lipid-nanoparticle-mediated in vivo genome editing in the lungs and spleen by disrupting Cas9 activity in the liver by Sago, Cory D., Lokugamage, Melissa P., Loughrey, David, Lindsay, Kevin E., Hincapie, Robert, Krupczak, Brandon R., Kalathoor, Sujay, Sato, Manaka, Echeverri, Elisa Schrader, Fitzgerald, Jordan P., Gan, Zubao, Gamboa, Lena, Paunovska, Kalina, Sanhueza, Carlos A., Hatit, Marine Z. C., Finn, M. G., Santangelo, Philip J., Dahlman, James E.

“…Systemically delivered lipid nanoparticles are preferentially taken up by hepatocytes. This hinders the development of effective, non-viral means of editing…”
Get full text

Hypertension and incident cardiovascular events after next-generation BTKi therapy initiation by Chen, Sunnia T, Azali, Leylah, Rosen, Lindsay, Zhao, Qiuhong, Wiczer, Tracy, Palettas, Marilly, Gambril, John, Kola-Kehinde, Onaopepo, Ruz, Patrick, Kalathoor, Sujay, Rogers, Kerry, Kittai, Adam, Grever, Michael, Awan, Farrukh, Byrd, John C, Woyach, Jennifer, Bhat, Seema A, Addison, Daniel

“…Post-market analyses revealed unanticipated links between first-generation Bruton's tyrosine kinase inhibitor (BTKi) therapy, ibrutinib, and profound early…”
Get full text

COMPLETE HEART BLOCK: AN UNUSUAL PRESENTATION OF GIANT CELL MYOCARDITIS by Pastapur, Aishwarya, Kalathoor, Sujay, Issa, Rafik, Osobamiro, Oyinkansola, Naik, Mitha, Heider, Amer, Wanamaker, Brett, Liang, Jackson J., Tam, Marty

Get full text

Abstract 4125252: Pre-Hematopoietic Stem Cell Transplantation Echocardiographic Indices and Post-Transplant Cardiovascular Outcomes by Kalathoor, Sujay, Vasbinder, Alexi, Catalan, Tonimarie, Machado, Kristen, Ismail, Anis, Hutten, Christina, Pizzo, Ian, Huang, Yiyuan, Blakely, Pennelope, Banerjee, Mousumi, Leja, Monika, Hayek, Salim

“…Abstract only Introduction: Hematopoietic stem cell transplantation (HSCT) is associated with adverse cardiovascular (CV) events including the development of…”
Get full text

Ventricular arrhythmias and sudden death events following acalabrutinib initiation by Bhat, Seema A., Gambril, John, Azali, Leylah, Chen, Sunnia T., Rosen, Lindsay, Palettas, Marilly, Wiczer, Tracy E., Kalathoor, Sujay, Zhao, Qiuhong, Rogers, Kerry A., Kittai, Adam, Grever, Michael, Awan, Farrukh, Ruz, Patrick, Byrd, John C., Woyach, Jennifer, Addison, Daniel

“…•Patients treated with next generation BTKi therapy acalabrutinib still see a >8 fold risk of ventricular arrhythmia and sudden death events.•Ventricular…”
Get full text

Myeloid cell heterogeneity in the tumor microenvironment and therapeutic implications for childhood central nervous system (CNS) tumors by Kalathoor, Sujay, Rajendran, Sakthi, Canella, Alessandro, Raval, Raju, Cripe, Timothy P., Mardis, Elaine R., Rajappa, Prajwal

“…Central nervous system (CNS) tumors are the most common type of solid tumors in children and the leading cause of cancer deaths in ages 0–14. Recent advances…”
Get full text

Abstract 12000: Ventricular Arrhythmias and Sudden Death Events Following Acalabrutinib Therapy Initiation for Hematology Malignancies by Gambril, John, Bhat, Seema A, Azali, Leylah, Chen, Sunnia, Rosen, Lindsay, Palettas, Marilly, Wiczer, Tracy, Kalathoor, Sujay, Zhao, Qiuhong, Rogers, Kerry, Kittai, Adam, Grever, Michael, Awan, Farrukh, Ruz, Patrick, Byrd, John C, Woyach, Jennifer, Addison, Daniel

“…IntroductionAcalabrutinib, a next generation Bruton’s tyrosine kinase inhibitor (BTKi) associates with dramatic efficacy against hematology malignancies…”
Get full text

Abstract 17859: Real World Cardiovascular Events With Next Generation Bruton's Tyrosine Kinase Inhibitors - An Updated Analysis by Poliner, Michael C, Buck, Benjamin, Ghazi, Sanam, Chen, Sunnia, Gambril, John A, Sansoterra, Stephen, Wiczer, Tracy, Bhat, Seema, Azali, Leylah, Rosen, Lindsay, Kalathoor, Sujay, Zhao, Qiuhong, Rogers, Kerry, Kittai, Adam, Grever, Michael, Awan, Farrukh, Ruz, Patrick, Palettas, Marilly, Ferdousi, Mussammat, Kola-Kehinde, Onaopepo, Sharma, Sneha, Byrd, John, Woyach, Jennifer, Addison, Daniel

“…Abstract only Introduction: Acalabrutinib and zanubrutinib are next generation Bruton’s tyrosine kinase inhibitors (BTKIs) associated with dramatic efficacy…”
Get full text

Representation of women in clinical trials supporting FDA‐approval of contemporary cancer therapies by Kalathoor, Sujay, Ghazi, Sanam, Otieno, Beryl, Babcook, Melissa A., Chen, Sunnia, Nidhi, Neha, Bae, Junu, Pierre‐Charles, Jovan, Breathett, Khadijah, Mazimba, Sula, Johnson, Amber, Brewer, LaPrincess, Mohammed, Selma, Carter, Rebecca R., Bonsu, Janice M., Ferdousi, Mussammat, Kola‐Kehinde, Onaopepo, McLaughlin, Eric, Brammer, Jonathan, Ruz, Patrick, Khan, Sarah, Odei, Bismarck, Mitchell, Darrion, Wei, Lai, Patel, Prem, Paskett, Electra D., Addison, Daniel

“…Contemporary anticancer therapies frequently have different efficacy and side effects in men and women. Yet, whether women are well‐represented in pivotal…”
Get full text

Cardiovascular Toxicities of BTK Inhibitors in Chronic Lymphocytic Leukemia: JACC: CardioOncology State-of-the-Art Review by Quartermaine, Cooper, Ghazi, Sanam M, Yasin, Aneeq, Awan, Farrukh T, Fradley, Michael, Wiczer, Tracy, Kalathoor, Sujay, Ferdousi, Mussammat, Krishan, Satyam, Habib, Alma, Shaaban, Adnan, Kola-Kehinde, Onaopepo, Kittai, Adam S, Rogers, Kerry A, Grever, Michael, Ruz, Patrick, Bhat, Seema, Dickerson, Tyler, Byrd, John C, Woyach, Jennifer, Addison, Daniel

“…Over the past decade, the treatment landscape of chronic lymphocytic leukemia (CLL) has dramatically changed, shifting from cytotoxic chemotherapy to targeted…”
Get full text

Oxidized Cholesterol: Nanoparticles Containing Oxidized Cholesterol Deliver mRNA to the Liver Microenvironment at Clinically Relevant Doses (Adv. Mater. 14/2019) by Paunovska, Kalina, Da Silva Sanchez, Alejandro J., Sago, Cory D., Gan, Zubao, Lokugamage, Melissa P., Islam, Fatima Z., Kalathoor, Sujay, Krupczak, Brandon R., Dahlman, James E.

“…Using mRNA to produce therapeutic proteins is a promising approach to treat genetic diseases. However, systemically delivering mRNA to cell types besides…”
Get full text

Cardiovascular Toxicities of BTK Inhibitors in Chronic Lymphocytic Leukemia: State-of-the-Art Review by Quartermaine, Cooper, Ghazi, Sanam M., Yasin, Aneeq, Awan, Farrukh T., Fradley, Michael, Wiczer, Tracy, Kalathoor, Sujay, Ferdousi, Mussammat, Krishan, Satyam, Habib, Alma, Shaaban, Adnan, Kola-Kehinde, Onaopepo, Kittai, Adam S., Rogers, Kerry A., Grever, Michael, Ruz, Patrick, Bhat, Seema, Dickerson, Tyler, Byrd, John C., Woyach, Jennifer, Addison, Daniel

“…Over the past decade, the treatment landscape of chronic lymphocytic leukemia (CLL) has dramatically changed, shifting from cytotoxic chemotherapy to targeted…”
Get full text

Cardiovascular Toxicities of BTK Inhibitors in Chronic Lymphocytic Leukemia by Quartermaine, Cooper, Ghazi, Sanam M., Yasin, Aneeq, Awan, Farrukh T., Fradley, Michael, Wiczer, Tracy, Kalathoor, Sujay, Ferdousi, Mussammat, Krishan, Satyam, Habib, Alma, Shaaban, Adnan, Kola-Kehinde, Onaopepo, Kittai, Adam S., Rogers, Kerry A., Grever, Michael, Ruz, Patrick, Bhat, Seema, Dickerson, Tyler, Byrd, John C., Woyach, Jennifer, Addison, Daniel

“…Over the past decade, the treatment landscape of chronic lymphocytic leukemia (CLL) has dramatically changed, shifting from cytotoxic chemotherapy to targeted…”
Get full text